O13 - 2022 Mpox outbreak: Challenges and Innovations

Moderator(s)

• LB

  Lindley Barbee, MD, MPH

  University of Washington, United States
• 

  Otilia Mårdh, MD, MSc

  Scientific officer HIV, STI and Viral Hepatitis
  European Centre for Diseases Prevention and Control (ECDC), Stockholms Lan, Sweden

Presentations:

• 10:00 – 10:15 CST

  Mpox in Germany, 2022: a shift from event-linked travel-associated transmission to a large autochthonous outbreak
  

  Primary Presenter: Klaus Jansen, Dphil (he/him/his) – Robert Koch Institute
• 10:15 – 10:30 CST

  Clinically inapparent mpox cases among visitors of three anonymous HIV/STI testing centers in Berlin, Germany, April–October, 2022
  

  Primary Presenter: Uwe Koppe, Dr. rer. nat. (he/him/his) – Robert Koch Institute
• 10:30 – 10:45 CST

  Case-Control Study of Risk Factors Associated with Mpox, San Francisco, CA, July–October, 2022
  

  Primary Presenter: Julia M. Janssen, MD – San Francisco Department of Public Health
• 10:45 – 11:00 CST

  MPOX AMONG MSM IN THE NETHERLANDS PRIOR TO MAY 2022, A RETROSPECTIVE STUDY
  

  Primary Presenter: Henry de Vries, Md PhD – Public Health Service Amsterdam and Amsterdam University Medical Centre
• 11:00 – 11:15 CST

  Characteristics of mpox positive, versus mpox negative, and mpox unsuspected clients from the Centre of Sexual Health, Public Health Service of Amsterdam, 20 May to 15 September 2022
  

  Primary Presenter: Henry de Vries, Md PhD – Public Health Service Amsterdam and Amsterdam University Medical Centre
• 11:15 – 11:30 CST

  Rectal and Pharyngeal Mpox PCR Testing of Men Who Have Sex with Men (MSM) Suggests that Rectal Testing is More Sensitive than Lesion Testing and that Most Infections Are Asymptomatic
  

  Primary Presenter: Matthew R. Golden, MD, MPH – University of Washington